The AdaptV platform optimizes study designs across your team with new capabilities to improve group sequential designs, response adaptive randomization, and BOIN I/II designs.
Boston, June 17, 2024 /PRNewswire/ — Phase Va pioneer in software and machine learning (ML) for adaptive clinical trial optimization, today announced that its Adapt V A platform for optimal design and closed-loop execution of adaptive clinical trials.
The AdaptV platform enables optimal clinical trial design through a user-friendly interface that supports advanced interactive visualizations. It integrates a wide range of data sources and ML algorithms, enabling rapid iteration.
of Adapt V The platform leverages an intuitive user interface and flexible software architecture along with proprietary algorithms, reinforcement learning, and causal ML to facilitate broad adoption of advanced, adaptive clinical trials. The updated platform maximizes efficiency and increases trial success rates, further reducing costs and shortening trial duration to benefit patients.
“Our platform enables clinical trial teams and strategic stakeholders to better understand the critical decision trade-offs required throughout an adaptive trial design and make optimal decisions at any point during the trial,” said Raviv Pryluk, PhD, CEO and co-founder of PhaseV. “By helping them overcome inherent complexities, we unlock the vast potential of adaptive trials, accelerating their adoption to support more efficient drug development and commercialization.”
Launched in 2023, PhaseV's core technology has been adopted by dozens of pharmaceutical companies, CROs and biotech players in the U.S. and around the world. Europe.
Latest version Adapt V It includes an advanced mode that supports more detailed modification of all algorithmic and statistical parameters involved in the study design, taking into account the unique characteristics of a particular study, and also incorporates new proprietary algorithms for several types of adaptive study design.
- Group sequential design (GSD) is an adaptive design that supports multiarm trials while improving precision with small sample sizes and maintaining strict controls to avoid declaring a drug successful when it is not working (type I error).
- New Response Adaptive Randomization (RAR) capability supports multiple interim trials in a study while maintaining the highest standards of interactivity and accuracy.
- Bayesian Optimal Interval Phase I/II Trial Design (BOIN12), in conjunction with FDA Project Optimus, aims to optimize and dose selection in oncology drug development. Adapt V The platform makes it possible to create BOIN12 designs in just minutes and easily make the real-time adaptations required during test execution.
About Phase V
By harnessing the power of advanced causal inference and pushing the limits of ML, PhaseV detects hidden signals in clinical data and extracts actionable insights to plan optimal next steps. The company's technology enables optimal design and closed-loop execution of adaptive clinical trials, improving efficiency and success rates. PhaseV is driving a paradigm shift in the world of clinical trials to bring new treatments to more patients more precisely and efficiently. Learn more here. home page And follow us LinkedIn.
Media Contact:
Ellie Hanson
PhaseV's FINN Partner
[email protected]
929-588-2008
Photo: https://mma.prnewswire.com/media/2440130/PhaseV.jpg
Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
SOURCE PhaseV
